VIDEO: Sialic acid-coated nanoparticle under investigation in nonexudative AMD
Click Here to Manage Email Alerts
SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Carl D. Regillo, MD, discusses AVD-104, a sialic acid-coated nanoparticle under investigation for the treatment of nonexudative age-related macular degeneration.
“It’s a whole new type of therapeutic approach that could be useful to treat geographic atrophy,” he said.
AVD-104 (Aviceda Therapeutics) showed efficacy in preclinical studies in the reduction of inflammation mediated by macrophages in animal models and did not cause any anatomic or functional adverse events, according to Regillo.
A phase 2/3 clinical trial of AVD-104 is now underway, he said.
Collapse
Regillo C. Modulation of macrophages and complement dysfunction in nonexudative AMD using new sialic acid-coated nanoparticles. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Read more about
Click Here to Manage Email Alerts